In its latest financial results, Cambridge, Mass.-based Vericel (NSDQ:VCEL) saw sales climb 60% for its permanent skin-replacement product, Epicel, designed for patients with severe burns. Sales for its autologous cellular scaffold, Maci, were up 20% following its launch to the commercial market.
Vericel’s growing product adoption helped to fuel the company’s first profitable quarter, according to CEO Nick Colangelo.
“Both products are the only FDA-approved products in their class and they’re highly efficacious,” he told Drug Delivery Business News.
Maci is the first FDA-approved implant to use healthy cartilage tissue from a patient’s own knee to grow cells on the scaffold. In a Phase III extension study of 128 patients, Vericel found that the pain and function improvements seen in a previous late-stage trial were maintained after five years for participants treated with Maci compared to microfracture.
Get the full story at our sister site, Drug Delivery Business News.